Digostics Asia Pte Ltd is the Singapore entity of the UK Headquartered startup, specializing in diagnostic home testing and digital health technology solutions.

It’s flagship product, GTT@home is a home use Oral Glucose Tolerance Test system that improves access, enhances compliance, and when experienced, is preferred by patients over the in-clinic process.

By utilizing small capillary blood samples, a home delivered kit and smartphone integration, patients and HCP’s appreciate the flexibility to deliver this essential test successfully, particularly in our primary focus of screening for Gestational Diabetes and Post-Partum follow up.

In real world use, GTT@home has many benefits in the diagnosis of dysglycaemia for Gestational Diabetes in Pregnancy, Type 1 Diabetes, Cystic Fibrosis related Diabetes, Population screening for Type 2 and Pre-Diabetes, as well as supporting Drug Trials.

GTT@home was designed and developed through close partnerships with Novartis and J&J. Today GTT@home is approved in Europe, UK, UAE and now HSA approved and currently under review in public hospitals, as well as Polyclinics and is in use by the NHS in the UK.

VISIT WEBSITE

For further enquiry, please contact Lewis Owens CEO Asia and Co-Founder